Algorae Pharmaceuticals Ltd
Company Profile
Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUST: +61 422180317
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
48
Stocks News & Analysis
stocks
ASX healthcare giant remains well positioned despite share slump
stocks
Australian bank remains overvalued despite strong result
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,322.30 | 0.80 | -0.01% |
| CAC 40 | 8,313.24 | 14.64 | -0.18% |
| DAX 40 | 24,856.15 | 131.70 | -0.53% |
| Dow JONES (US) | 50,121.40 | 66.74 | -0.13% |
| FTSE 100 | 10,472.11 | 118.27 | 1.14% |
| HKSE | 27,077.63 | 188.75 | -0.69% |
| NASDAQ | 23,066.47 | 36.01 | -0.16% |
| Nikkei 225 | 57,628.22 | 22.32 | -0.04% |
| NZX 50 Index | 13,513.48 | 6.20 | 0.05% |
| S&P 500 | 6,941.47 | 0.34 | -0.00% |
| S&P/ASX 200 | 9,082.20 | 20.20 | 0.22% |
| SSE Composite Index | 4,133.51 | 1.53 | 0.04% |